We often hear headlines about breakthrough discoveries and promising new therapies for herpes — only to hear nothing more about them months or even years later. Why do so many promising antiherpetic drugs fail to reach patients? Why does drug development take so long, and where are the biggest bottlenecks? Most importantly, is there a way to accelerate the process?
In this educational presentation, hosted by the Herpes Cure Advocacy (HCA), we will explore the full journey of drug development — from early discovery and laboratory research to clinical trials and regulatory approval — with a specific focus on antiviral and antiherpetic therapies.
Attendees will gain insight into the unique scientific and biological challenges that herpes simplex virus presents, including drug resistance, viral latency, and limitations of existing treatments. The presentation will also examine real-world case studies, tracing the development pathway of established antivirals such as valacyclovir (Valtrex) and reviewing emerging therapies including Pritelivir, IM-250, ABI-5366, and ABI-1179.
This session is designed for researchers, healthcare professionals, advocates, and community members who want a deeper understanding of why progress can be slow — and what success can look like when science, persistence, and collaboration align.
Speaker:
Luis Schang, MV, PhD
Date & Time:
Tuesday, January 13
6:00pm EST
Registration:
👉 https://us06web.zoom.us/meeting/register/_6eimmORTaSK2Z6QFIC4Nw#/registration